Armour Thyroid (thyroid tablets, USP)
Armour Thyroid tablets are pituitary thyroid-stimulating hormone suppressants used for the treatment of patients with thyroid cancer
Allergan offers 1 financial assistance program for patients using Armour Thyroid:
Allergan Patient Assistance Program
Patients who are unable to afford the cost of Armour Thyroid tablets and meet other eligibility requirements are eligible for free medication. Eligible applicants will be enrolled for 12 months and a 90-day supply of medication will be shipped immediately to the physician. Medicare Part D applicants must have been denied the low income subsidy and will only be enrolled until the end of the calendar year.
Cabometyx (cabozantinib) Tablets
Cabometyx is a kinase inhibitor used for the treatment of patients 12 years or older with locally advanced or metastatic differentiated thyroid cancer that has progressed after previous VEGFR-targeted therapy and who are not eligible or are refractory (don’t respond) to radioactive iodine therapy.
Exelixis offers 2 financial assistance programs for patients using Cabometyx:
EASE Co-Pay Program
Eligible patients who have private insurance will pay $0 per month for Cabometyx, with a maximum limit of $25,000 annually.
EASE Patient Assistance Program
This program provides Cabometyx free of charge to patients who do not have insurance coverage and who meet eligibility requirements.
Caprelsa (vandetanib) Tablets
Caprelsa is a kinase inhibitor used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced or metastatic disease.
Caprelsa Access Support offers 3 financial assistance programs for patients using Caprelsa:
Caprelsa Co-Pay Assistance Program
Patients with private insurance whose out-of-pocket costs associated with Caprelsa are more than $50 may be eligible for assistance of up to the program maximum, annually.
Caprelsa Interim Access Program
This program provides a short-term supply of Caprelsa free of charge to patients with private insurance who are experiencing a delay in receiving coverage for this medication.
Caprelsa Patient Assistance Program
For eligible patients who are uninsured or underinsured, this program may provide Caprelsa free of charge.
Cometriq (cabozantinib) Capsules
Cometriq is a kinase inhibitor used for the treatment of patients with progressive, metastatic medullary thyroid cancer.
Exelixis offers 2 financial assistance programs for patients using Cometriq:
EASE Co-Pay Program
Eligible patients who have private insurance will pay $0 per month for Cometriq, with a maximum limit of $25,000 annually.
EASE Patient Assistance Program
This program provides Cometriq free of charge to patients who do not have insurance coverage and who meet eligibility requirements.
Gavreto (pralsetinib) Capsules
Gavreto is an oral RET kinase inhibitor used for the treatment of patients 12 years or older with advanced or metastatic medullary thyroid cancer and RET mutation who require systemic therapy. Gavreto is also used for the treatment of patients 12 years or older with advanced or metastatic thyroid cancer and RET fusion who require systemic therapy and whose tumor is refractory to radioactive iodine (if radioactive iodine is appropriate).
Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Gavreto:
Genentech Oncology Co-pay Assistance Program
Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Gavreto, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.
Genentech Patient Foundation
This foundation provides Gavreto free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.
Lenvima (lenvatinib) Capsules
Lenvima is a kinase inhibitor and single agent used for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
Eisai offers 2 financial assistance programs for patients using Lenvima:
Lenvima $0 Co-pay Program
Privately insured patients may be eligible for this program, which offers a $0 copay for each prescription, with a $40,000 annual limit.
Eisai Assistance Program
This program provides Lenvima at no cost to financially needy patients who meet program eligibility criteria.
Mekinist (trametinib)
Mekinist is a kinase inhibitor used, in combination with Tafinlar, for the treatment of patients with unresectable or metastatic anaplastic thyroid cancer and a BRAF V600E mutation.
Novartis Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Mekinist:
Novartis Oncology Universal Co-pay Program
Through this program, patients who have private insurance will be responsible for up to $25 monthly in copay and coinsurance. The program pays the balance up to a maximum of $15,000 yearly.
Novartis Patient Assistance Foundation
To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Mekinist for free until prescription drug coverage becomes available to them.
Nexavar (sorafenib) Tablets
Nexavar is a kinase inhibitor used for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma, refractory to radioactive iodine treatment.
Bayer’s Resources for Expert Assistance and Care Helpline (REACH) offers 2 financial assistance programs for patients using Nexavar:
Nexavar $0 Co-Pay Program
With this program, patients with private insurance pay a $0 copay for Nexavar, and the program pays up to $25,000, with no monthly maximum.
Bayer US Patient Assistance Foundation
This foundation provides free medicine for patients who are prescribed a Bayer medication and are uninsured or underinsured and meet certain eligibility criteria.
Retevmo (selpercatinib) Capsules
Retevmo is RET kinase inhibitor used for the treatment of patients 12 years or older with advanced or metastatic medullary thyroid cancer and RET mutation who require systemic therapy. Retevmo is also used for the treatment of patients 12 years or older with advanced or metastatic thyroid cancer and RET fusion who require systemic therapy and whose tumor is refractory to radioactive iodine (if radioactive iodine is appropriate).
Lilly Oncology offers 2 financial assistance programs for patients who are prescribed Retevmo:
Retevmo Savings Card
Eligible patients who have private insurance may pay as little as $0 for a 30-day supply of Retevmo, subject to a monthly cap of wholesale acquisition cost plus usual and customary pharmacy charges and a maximum annual benefit of $25,000.
Lilly Cares Foundation Patient Assistance Program
For eligible patients who are uninsured or underinsured, and who have a household income at or below 500% of the federal poverty level, this program provides Retevmo for free.
Synthroid (levothyroxine sodium tablets, USP)
Synthroid is used as an adjunct to surgery and radio- iodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
AbbVie offers 2 financial assistance programs for patients using Synthroid:
Synthroid Delivers Program
Patients who have a prescription for Synthroid, regardless of insurance coverage, can receive 30 tablets for $29.50; 60 tablets for $54; and 90 tablets for $75. Patients enrolling in this program may not utilize insurance benefits, including any federal, state, or government-funded insurance program.
AbbVie Patient Assistance Foundation
Patients without insurance and with limited income may qualify to receive free Synthroid. Patients enrolled in Medicare Part D or another insurance program may be eligible for assistance on an exception basis.
Tafinlar (dabrafenib)
Tafinlar is a kinase inhibitor used, in combination with Mekinist, for the treatment of patients with unresectable or metastatic anaplastic thyroid cancer and a BRAF V600E mutation.
Novartis Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Tafinlar:
Novartis Oncology Universal Co-pay Program
Through this program, patients with private insurance will be responsible for up to $25 monthly in copay and co-insurance. The program pays the balance up to a maximum of $15,000 yearly.
Novartis Patient Assistance Foundation
To be eligible for financial assistance through this program, patients without insurance must provide proof of income that meets the financial eligibility requirements. Eligible patients who are US citizens may receive Tafinlar for free until prescription drug coverage becomes available to them.
Thyrogen (thyrotropin alfa)
Thyrogen is used as an adjunctive diagnostic tool for testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy. Thyrogen is also used as an adjunctive treatment in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.
Sanofi Genzyme offers 2 financial assistance programs for patients using Thyrogen:
Thyrogen Co-Pay Assistance Program
Eligible patients qualify for a $0 copay, up to a maximum copay assistance amount of $1,000 annually. This may include any combination of copay, co-insurance, or deductible.
Sanofi Genzyme Patient Assistance Program
For patients without insurance or those whose insurance plan does not cover Thyrogen, this Patient Assistance Program may be able to provide Thyrogen free of charge. To learn more, or to determine if you may qualify for assistance, contact your doctor’s office.
Tirosint (levothyroxine sodium)
Tirosint capsules work as pituitary thyrotropin-stimulating hormone suppression and are used for the treatment of patients with thyrotropin-dependent well-differentiated thyroid cancer, as an adjunct to surgery and radioiodine therapy.
IBSA Pharma offers 2 financial assistance programs for patients using Tirosint:
Tirosint Co-Pay Savings Card
With this savings card, patients are responsible for the first $25 and will receive up to $85 off their out-of-pocket expenses. Insured and cash-paying patients are eligible for the savings card. Medicare and Medicaid patients are not eligible for the program.
Tirosint Direct Program
Through this program, patients can get Tirosint for as little as $50 for a 30-day supply or $120 for a 90-day supply, regardless of your insurance coverage.
Table. Drugs Prescribed for Thyroid Cancer
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Armour Thyroid (thyroid tablets, USP)
- Allergan
- Treatment of thyroid cancer
- Allergan Patient Assistance Program
800-222-6885
- Cabometyx (cabozantinib) Tablets
- Exelixis
- Treatment of patients 12 years or older with locally advanced or metastatic differentiated thyroid cancer that has progressed after previous VEGFR-targeted therapy and who are not eligible or are refractory to radioactive iodine therapy
- EASE Co-Pay Program
800-900-3273
EASE Patient Assistance Program
800-900-3273
- Caprelsa (vandetanib) Tablets
- Sanofi Genzyme
- Treatment of unresectable, locally advanced or metastatic medullary thyroid cancer
- Caprelsa Co-Pay Assistance Program
800-367-4999
Caprelsa Interim Access Program
800-367-4999
Caprelsa Patient Assistance Program
800-367-4999
- Cometriq (cabozantinib) Capsules
- Exelixis
- Treatment of progressive, metastatic medullary thyroid cancer
- EASE Co-Pay Program
844-900-3273
EASE Patient Assistance Program
844-900-3273
- Gavreto (pralsetinib) Capsules
- Genentech
- Treatment of patients 12 years or older with advanced or metastatic medullary thyroid cancer and RET mutation who require systemic therapy
Treatment of patients 12 years or older with advanced or metastatic thyroid cancer and RET fusion who require systemic therapy and whose tumor is refractory to radioactive iodine - Genentech Oncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Lenvima (lenvatinib) Capsules
- Eisai
- Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer
- Lenvima $0 Co-pay Program
866-613-4724
Eisai Assistance Program
866-613-4724
- Mekinist (trametinib)
- Novartis
- Treatment, in combination with Tafinlar, of unresectable or metastatic anaplastic thyroid cancer with a BRAF V600E mutation
- Novartis Oncology Universal Co-pay Program
800-245-5356
Novartis Patient Assistance Foundation
800-277-2254
- Nexavar (sorafenib) Tablets
- Bayer
- Treatment of locally recurrent or metastatic, progressive, differentiated thyroid cancer, refractory to radioactive iodine treatment
- Nexavar $0 Co-Pay Program
866-581-4992
Bayer US Patient Assistance Foundation
866-228-7723
- Retevmo (selpercatinib) Capsules
- Eli Lilly
- Treatment of patients 12 years or older with advanced or metastatic medullary thyroid cancer and RET mutation who require systemic therapy
Treatment of patients 12 years or older with advanced or metastatic thyroid cancer and RET fusion who require systemic therapy and whose tumor is refractory to radioactive iodine - Retevmo Savings Card
866-472-8663
Lilly Cares Foundation Patient Assistance Program
800-545-6962
- Synthroid (levothyroxine sodium tablets, USP)
- AbbVie
- Treatment of thyrotropin-dependent well-differentiated thyroid cancer, as an adjunct to surgery and radioiodine therapy
- Synthroid Delivers Program
844-GET-SYNTHROID
(844-438-796847643)
AbbVie Patient Assistance Foundation
800-222-6885
- Tafinlar (dabrafenib)
- Novartis
- Treatment, in combination with Mekinist, of unresectable or metastatic anaplastic thyroid cancer with a BRAF V600E mutation
- Novartis Oncology Universal Co-pay Program
800-245-5356
Novartis Patient Assistance Foundation
800-277-2254
- Thyrogen (thyrotropin alfa)
- Sanofi Genzyme
- Adjunctive diagnostic tool for testing for well-differentiated thyroid cancer with previous thyroidectomy
Adjunct treatment for radioiodine ablation of thyroid tissue remnants, after thyroidectomy for well-differentiated thyroid cancer - Thyrogen Co-Pay Assistance Program
888-497-6436
Sanofi Genzyme Patient Assistance Program
888-497-6436
- Tirosint (levothyroxine sodium)
- IBSA Pharma
- Treatment of thyrotropin-dependent well-differentiated thyroid cancer, as an adjunct to surgery and radioiodine therapy
- Tirosint Co-Pay Savings Card
833-666-2501
Tirosint Direct Program
833-666-2501